未名醫藥(002581.SZ):未名天源擬將自有設備及技術轉讓給營口化工
格隆匯 10 月 26日丨未名醫藥(002581.SZ)公佈,未名天源與營口營新化工科技有限公司(“營口化工”)籤訂《設備轉讓合同》,合同約定未名天源將自有設備及技術轉讓給營口化工,交易價格為人民幣4600萬元。
乙方轉讓給甲方的設備包括:原甲酸三甲脂設備、原甲酸三乙酯設備、原乙酸三甲酯設備、中試車間設備及其他設備。
乙方技術(含原甲酸酯類產品有關的專利及非專利技術)隨同轉讓設備無償交付甲方使用,並在《設備轉讓合同》生效後六個月內將專利技術過户給甲方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.